Actually, the molecules actually have three dimensional anomalies from one another. Clearly Merck was better at designing the lion’s share of the CI trials, but hard to say Keytruda’s differences otherwise make it better than Opdivo. Maybe Amgen will solve the mystery regarding why Keytruda seems to win out a little more often.
Market Data 
Markets 
AI
